High content CRISPR screens have become a leading method for the identification of new cellular pathways, proteins functions, and drug targets. However, as the complexity of these screens increase, so does the possibility of artifacts. Here, we describe a refined CRISPR screening protocol that can compare acute cellula...
Truc T. Losier, Karyn E. King, J. Taylor et al.· bioRxiv· 0 citations
Abstract Background Clear cell renal cell carcinoma (ccRCC) is defined by constitutive pseudohypoxia driven by von Hippel-Lindau (VHL) loss, pronounced intratumoral heterogeneity, and aberrant hypervascularity, features that collectively promote tumor progression and limit therapeutic durability. Although VEGF-targeted...
B. Ulukan, O. Saatci, A. Madrigal et al.· The Oncologist· 0 citations
Findings link PARP1 activity to translational control and SG formation, which may protect against cell death following DNA damage, and provide insight into PARP1- and stress granule-associated diseases, including cancer and neurodegeneration.
M. Tereshchenko, Rebecca Earnshaw, Christopher Chin Sang et al.· Journal of Cell Biology· 0 citations
Using single-cell transcriptomics, lysyl oxidase (LOX) is identified as a driver of ccRCC progression, selectively enriched in a hypoxia/epithelial-mesenchymal transition (EMT) gene program associated with poor outcome.
B. Ulukan, O. Saatci, A. Madrigal et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
